Phathom Pharmaceuticals (PHAT) Stock Price & Analysis
Score
AI Analysis
SnapshotPhathom Pharmaceuticals is a growth-led story right now — Growth 100/100 is the pillar doing the heavy lifting (overall 68/100) in Biotechnology. Under the hood: revenue compounding ~4109% annually over recent years. Street targets still imply ~172% upside.
Price History
Price: —
Fair value: —
—
P/E (TTM): —
Net Income (TTM): —
Score: —
—
Score Breakdown
Market percentile scores loading…
Value
Growth
Quality
Financial Summary
Phathom Pharmaceuticals, Inc. (PHAT) last printed $6.06. Equity value is $492.63M. Trailing earnings multiple —. The revenue row is reported history. Targets and ratings are on the forecast page.
Financials
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $682,000.00 | $55.25M | $175.11M |
About
Phathom Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to advancing and commercializing therapies for gastrointestinal ailments. A pivotal asset for the company is vonoprazan, a distinctive potassium-competitive acid blocker (P-CAB) designed to effectively inhibit gastric acid production, for which Phathom holds commercial rights across the United States, Europe, and Canada. This compound is currently undergoing advanced (Phase III) clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD), and also as a component of combination therapy with antibiotics to combat Helicobacter pylori (H. pylori) infection. Established in 2018, Phathom Pharmaceuticals maintains its corporate headquarters in Florham Park, New Jersey.